# Sanaria PfSPZ Challenge With Pyrimethamine Chemoprophylaxis (PfSPZ-CVac Approach): Phase 1 Trial to Determine Safety and Protective Efficacy of Sanaria PfSPZ Challenge With Concurrent Pyrimethamine Treatment That Inhibits Development of Asexual B...

> **NCT02511054** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 57 (actual)

## Conditions studied

- Malaria

## Interventions

- **DRUG:** Chloroquine (CQ)
- **DRUG:** Pyrimethamine (PYR)
- **BIOLOGICAL:** Sanaria PfSPZ Challenge (NF54)

## Key facts

- **NCT ID:** NCT02511054
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07-21
- **Primary completion:** 2016-10-21
- **Final completion:** 2017-06-01
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2017-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02511054

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02511054, "Sanaria PfSPZ Challenge With Pyrimethamine Chemoprophylaxis (PfSPZ-CVac Approach): Phase 1 Trial to Determine Safety and Protective Efficacy of Sanaria PfSPZ Challenge With Concurrent Pyrimethamine Treatment That Inhibits Development of Asexual B...". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02511054. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*